Immunogenicity and Reactogenicity of Ad26.COV2.S in Korean Adults: A Prospective Cohort Study.

Hak Jun Hyun Min Joo Choi Jung Yeon Heo Yu Bin Seo Eliel Nham Jin Gu Yoon Hye Seong Ji Yun Noh Hee Jin Cheong Woo-Joo Kim Ju-Yeon Choi Young Jae Lee Hye Won Lee Sung Soon Kim Byoungguk Kim Joon Young Song

Published in: Journal of Korean medical science (2022)

Single-dose Ad26.COV2.S was safe and immunogenic. NAb titer and S-specific T-cell immunity peak at 5-8 weeks and rather decrease at 10-12 weeks after vaccination. Cross-reactive neutralizing activity against the Omicron variant was negligible.

Keyphrases

respiratory syndrome coronavirus
sars cov
gestational age
coronavirus disease
advanced non small cell lung cancer
dengue virus